Compare Moderna, Inc. (MRNA) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Texas Instruments Incorporated — how do they compare? Moderna, Inc. trades at $137.39 (market cap $56.02B), while Texas Instruments Incorporated trades at $262.57 (market cap $236.46B). The key difference: Texas Instruments Incorporated is far larger — about 4.2× Moderna, Inc.'s market cap, and Texas Instruments Incorporated pays a 2.19% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TXN | |
|---|---|---|
Market Cap | $56.02B | $236.46B |
Sector | Health | Technology |
52-Week High | $174.38 | $332.35 |
52-Week Low | $22.36 | $153.33 |
Enterprise Value | $52.17B | $243.51B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Texas Instruments (TXN) trades at $261.59, up 1.22% with a bearish technical signal. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026. Revenue growth is recovering from 2024 lows, with 2025 revenue at $17.68B and net income of $5.00B. Analyst consensus is bullish with a $329.74 price target, though technical indicators show resistance near $262.
The outlook remains positive with strong profitability margins and AI-driven demand, but risks include rising debt levels and competitive pressures. The stock offers potential upside from current levels if earnings momentum continues, supported by institutional buy ratings and strategic positioning in analog chips.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
